AFP and hepatocellular carcinoma: In the setting of second line treatments, regorafenib and cabozantinib were approved for patients with HCC progression and ramucirumab for patients previously treated with sorafenib, with a serum AFP (Alpha-Fetoprotein) level ≥400 ng/mL [7].